UPDATE: RBC Capital Upgrades Prothena Corp (PRTA) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Prothena Corp. (PRTA) Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD 2021
February 24, 2021 5:06 PM ESTProthena Corporation plc (NASDAQ: PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid and neurodegenerative diseases, today announced three oral presentations and participation in a live forum at The 15th International Conference on Alzheimers and Parkinsons Diseases (AD/PD 2021). Prothena will present new preclinical data demonstrating that targeting a novel epitope with PRX005, an anti-tau antibody, resulted in superior attributes for the potential treatment of Alzheimers disease. PRX005 is being developed as part of the Companys global neuroscience collaboration with... More
